Tech Company Financing Transactions
Solstice Biologics Funding Round
Solstice Biologics closed a $18 million Series A funding round on 1/5/2013. Investors included venBio and Aeris Capital AG.
Transaction Overview
Company Name
Announced On
1/5/2013
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series A
Investors
venBio (Lead Investor) (Corey Goodman)
Aeris Capital AG (George Rehm)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1700 Owens St. 595
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Email Address
Not Recorded
Overview
Solstice Biologics is a private company focused on solving the problem of targeting and delivery of nucleic acid therapeutics. The company is developing small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Founder
Steven Dowdy
Browse more venture capital transactions:
Prev: 1/4/2013: EndoChoice venture capital transaction
Next: 1/5/2013: Vobi venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs